Full Coverage

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory...

                   
prnewswire.com
May 20, 2008
        
Story Timeline:  198 days

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor,... [read full story]                    

Add Comment
Latest article on this story:

Ardea Reports Positive Results From Preclinical Studies of HIV Drug

 redorbit.com May 23, 2008
First article on this story:

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory...

 earthtimes.org May 20, 2008
Selected publications with coverage of this story:
redorbit.com prnewswire.com medicalnewstoday.com yahoo.com earthtimes.org drugs.com pharmiweb.co.uk finanznachrichten.de
RELATED
Found 8 documents:
                   

Ardea Reports Positive Results From Preclinical Studies of HIV Drug

redorbit.com
May 23, 2008
        

Posted on: Friday, 23 May 2008, 12:00 CDT Ardea Biosciences has announced that its non-nucleoside reverse transcriptase inhibitor candidate, RDEA806, demonstrated no reproductive toxicity in preclinical studies. Animal reproductive toxicity studies recently completed with RDEA806 have...

                   

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory...

drugs.com
May 22, 2008
        

-- Phase 1 RDEA119 data expected in second half of 2008 -- SAN DIEGO, May 20, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that data was presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,...

                   

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

drugs.com
May 22, 2008
        

- Lead Candidate, RDEA806, Demonstrated No Reproductive Toxicity in Preclinical Study - SAN DIEGO, May 22, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced preclinical data on its lead non-nucleoside reverse transcriptase... ... Lead Candidate,...

                   

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program (PR...

yahoo.com
May 22, 2008
        

Ardea Biosciences, Inc. today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor candidate, RDEA806, demonstrating no reproductive toxicity. In addition, novel second-generation NNRTI, RDEA427, was selected as a development candidate for the potential treatment...

                   

Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program

earthtimes.org
May 22, 2008
        

Lead Candidate, RDEA806, Demonstrated No Reproductive Toxicity in Preclinical Study - - Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor (NNRTI) candidate, RDEA806, demonstrating no reproductive toxicity. In...

                   

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory...

yahoo.com
May 20, 2008
        

Tuesday May 20, 6:30 pm ET -- News ) today announced that data was presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating potent activity in mouse models of colitis. "These data further support the potential use of orally administered MEK inhibitors,...

                   

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory...

finanznachrichten.de
May 20, 2008
        

SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that data was presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating potent activity in mouse models of colitis. "These data further support the potential use of...

                   

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory...

earthtimes.org
May 20, 2008
        

Phase 1 RDEA119 data expected in second half of 2008 -- -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data was presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, demonstrating potent activity in mouse models of colitis. "These data further...